Literature DB >> 34792539

SARS-CoV-2 Spike-Specific T-Cell Responses in Patients With B-Cell Depletion Who Received Chimeric Antigen Receptor T-Cell Treatments.

Kalpana Parvathaneni1,2, Kyabeth Torres-Rodriguez3, Wenzhao Meng1, Wei-Ting Hwang4, Noelle Frey5, Ali Naji6, Vijay G Bhoj1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 34792539      PMCID： PMC8603228          DOI： 10.1001/jamaoncol.2021.6030

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  9 in total

Review 1.  Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy.

Authors:  Kitsada Wudhikarn; Miguel-Angel Perales
Journal:  Bone Marrow Transplant       Date:  2022-07-15       Impact factor: 5.174

2.  Enhanced BNT162b2 vaccine-induced cellular immunity in anti-CD19 CAR T cell-treated patients.

Authors:  Bernice Ling Zhi Oh; Nicole Tan; Ruklanthi de Alwis; Kamini Kunasegaran; Zhiwei Chen; Michelle Poon; Esther Chan; Jenny G H Low; Allen Eng Juh Yeoh; Antonio Bertoletti; Nina Le Bert
Journal:  Blood       Date:  2022-07-14       Impact factor: 25.476

3.  SOLVx therapeutics vaccine - Activate T-cell immunity using broad surveillance epitope strategy against mutant strains SARS-COV2.

Authors:  Md Shamsuddin Sultan Khan; John A Catanzaro
Journal:  Biomed Pharmacother       Date:  2022-05-30       Impact factor: 7.419

Review 4.  Severe acute respiratory syndrome coronavirus 2 variants-Possibility of universal vaccine design: A review.

Authors:  Eunhye Yoon; Dahyun Kim; Hyeeun Jeon; Yejin Kwon; Yejin Jang; Sulhee Kim; Kwang Yeon Hwang
Journal:  Comput Struct Biotechnol J       Date:  2022-06-23       Impact factor: 6.155

Review 5.  Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer.

Authors:  Arielle Elkrief; Julie T Wu; Chinmay Jani; Kyle T Enriquez; Michael Glover; Mansi R Shah; Hira Ghazal Shaikh; Alicia Beeghly-Fadiel; Benjamin French; Sachin R Jhawar; Douglas B Johnson; Rana R McKay; Donna R Rivera; Daniel Y Reuben; Surbhi Shah; Stacey L Tinianov; Donald Cuong Vinh; Sanjay Mishra; Jeremy L Warner
Journal:  Cancer Discov       Date:  2021-12-10       Impact factor: 38.272

6.  Reduced Antibodies and Innate Cytokine Changes in SARS-CoV-2 BNT162b2 mRNA Vaccinated Transplant Patients With Hematological Malignancies.

Authors:  Cristina Bergamaschi; Maria Pagoni; Margherita Rosati; Matthew Angel; Ifigeneia Tzannou; Margarita Vlachou; Ismini Darmani; Amirah Ullah; Jenifer Bear; Santhi Devasundaram; Robert Burns; Ioannis Baltadakis; Stavros Gigantes; Meletios-Athanasios Dimopoulos; George N Pavlakis; Evangelos Terpos; Barbara K Felber
Journal:  Front Immunol       Date:  2022-05-25       Impact factor: 8.786

7.  Immune response to three doses of mRNA SARS-CoV-2 vaccines in CD19-targeted chimeric antigen receptor T cell immunotherapy recipients.

Authors:  Pierre Sesques; Emmanuel Bachy; Emmanuelle Ferrant; Violaine Safar; Morgane Gossez; Florence Morfin-Sherpa; Fabienne Venet; Florence Ader
Journal:  Cancer Cell       Date:  2022-01-25       Impact factor: 31.743

8.  SARS-CoV-2-specific T-cell responses to recurrent COVID-19 pneumonitis in a patient with post-CART B-cell aplasia.

Authors:  Angus Hodder; Lindsey Williams; Jan Chu; Alasdair Bamford; Charlene Rodrigues; Kimberley Gilmour; Arnold Awuah; Fariba Tahami; Caroline Dalton; Orlagh McGarrity; Ajay Vora
Journal:  Blood Adv       Date:  2022-03-08

9.  Management of Chronic Graft-vs.-Host Disease in Children and Adolescents With ALL: Present Status and Model for a Personalised Management Plan.

Authors:  Agnieszka Sobkowiak-Sobierajska; Caroline Lindemans; Tomas Sykora; Jacek Wachowiak; Jean-Hugues Dalle; Halvard Bonig; Andrew Gennery; Anita Lawitschka
Journal:  Front Pediatr       Date:  2022-02-18       Impact factor: 3.418
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.